SPEAR UltraDetect™ for Neurodegenerative Biomarker Detection & Monitoring

• A novel immunoassay platform enabling ultra-sensitive detection of neurological biomarker detection 
• Quantitative plasma pTau 217 measurement with enhanced discrimination of amyloid positivity in both memory clinic and community cohorts  
• Beyond pTau 217: advancing Alzheimer’s and Parkinson’s disease research with the SPEAR UltraDetect™ biomarker solution

Speakers:

Feng Xuan

Co-Founder & Chief Executive Officer

Spear Bio Inc.